share_log

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio to Participate in the Virtual Investor Closing Bell Series

Palisade Bio将参加虚拟投资者收盘钟系列活动
Palisade Bio ·  06/24 00:00

Live video webcast on Wednesday, June 26th at 4:00 PM ET

6月26日星期三将进行现场视频网络直播th美国东部时间下午4:00

Carlsbad, CA, June 24, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it will participate in the Virtual Investor Closing Bell Series on Wednesday, June 26, 2024 at 4:00 PM ET.

加州卡尔斯巴德,2024年6月24日—Palisade Bio公司。(纳斯达克:PALI)(“Palisade”或“公司”),一家专注于开发和推进针对自身免疫性、炎性和纤维化疾病的新型治疗方法的生物制药公司,今天宣布将参加“虚拟投资者收盘钟系列活动”,时间为2024年6月26日星期三下午4:00 ET。

As part of the event, J.D. Finley, Chief Executive Officer, and Dr. Mitch Jones, Chief Medical Officer, of Palisade Bio will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

作为活动的一部分,Palisade Bio 的首席执行官 J.D. Finley 和首席医疗官 Dr. Mitch Jones 将提供公司概况和业务前景。除了主持的讨论,投资者和有兴趣的各方还将有机会在活动期间直播提交问题。公司将在允许的时间内回答尽可能多的问题。

A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (www.palisadebio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About Palisade Bio

关于Palisade Bio

Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.

Palisade Bio是一家生物制药公司,专注于开发和推进新型治疗自身免疫、炎症和纤维化疾病的药物。该公司相信,通过使用其新型治疗方法,将改变治疗局面。有关详细信息,请访问公司网站www.palisadebio.com.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247
PALI@jtcir.com

投资者关系联系人
JTC团队有限责任公司
Jenene Thomas
833-475-8247
PALI@jtcir.com

Source: Palisade Bio

资料来源:Palisade Bio

Primary Logo

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发